These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15623646

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. The role of CD22 and other inhibitory co-receptors in B-cell activation.
    Nitschke L.
    Curr Opin Immunol; 2005 Jun; 17(3):290-7. PubMed ID: 15886119
    [Abstract] [Full Text] [Related]

  • 44. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2739-46. PubMed ID: 19351771
    [Abstract] [Full Text] [Related]

  • 45. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
    Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S, Rybak SM.
    Biochem Biophys Res Commun; 2005 Jun 03; 331(2):595-602. PubMed ID: 15850802
    [Abstract] [Full Text] [Related]

  • 46. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I.
    Int J Cancer; 1999 Mar 31; 81(1):148-55. PubMed ID: 10077166
    [Abstract] [Full Text] [Related]

  • 47. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.
    Clin Cancer Res; 2011 Oct 15; 17(20):6448-58. PubMed ID: 22003072
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y.
    Cancer Res; 2008 Apr 01; 68(7):2400-8. PubMed ID: 18381448
    [Abstract] [Full Text] [Related]

  • 51. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
    Takeshita A, Yamakage N, Shinjo K, Ono T, Hirano I, Nakamura S, Shigeno K, Tobita T, Maekawa M, Kiyoi H, Naoe T, Ohnishi K, Sugimoto Y, Ohno R.
    Leukemia; 2009 Jul 01; 23(7):1329-36. PubMed ID: 19369961
    [Abstract] [Full Text] [Related]

  • 52. CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity.
    Chen J, McLean PA, Neel BG, Okunade G, Shull GE, Wortis HH.
    Nat Immunol; 2004 Jun 01; 5(6):651-7. PubMed ID: 15133509
    [Abstract] [Full Text] [Related]

  • 53. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR, Damle NK.
    Cancer Immunol Immunother; 2007 Jul 01; 56(7):1107-17. PubMed ID: 17160682
    [Abstract] [Full Text] [Related]

  • 54. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M.
    Haematologica; 2006 Feb 01; 91(2):176-83. PubMed ID: 16461301
    [Abstract] [Full Text] [Related]

  • 55. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
    Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.
    Cancer Res; 2005 Sep 15; 65(18):8331-8. PubMed ID: 16166310
    [Abstract] [Full Text] [Related]

  • 56. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms.
    Poe JC, Fujimoto Y, Hasegawa M, Haas KM, Miller AS, Sanford IG, Bock CB, Fujimoto M, Tedder TF.
    Nat Immunol; 2004 Oct 15; 5(10):1078-87. PubMed ID: 15378059
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide.
    Bakker TR, Piperi C, Davies EA, Merwe PA.
    Eur J Immunol; 2002 Jul 15; 32(7):1924-32. PubMed ID: 12115612
    [Abstract] [Full Text] [Related]

  • 60. Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.
    Krauss J, Arndt MA, Vu BK, Newton DL, Rybak SM.
    Br J Haematol; 2005 Mar 15; 128(5):602-9. PubMed ID: 15725080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.